Vertex Pharmaceuticals (NasdaqGS:VRTX) presented promising clinical data on their CFTR modulator ALYFTREK at the European Cystic Fibrosis Conference, showcasing improved outcomes for patients with ...

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has announced data across multiple studies demonstrating positive clinical ...

Vertex Pharmaceuticals Incorporated today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ...

Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Vertex Pharmaceuticals has caught investors’ eyes, but its stock performance isn’t exactly a mic-drop moment. Despite massive ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

NEW YORK – Medical experts emphasized the importance of considering different patient needs when deciding which treatments to employ for pain management at a May 29 Axios event. Axios' Maya Goldman ...

Vertex Pharmaceuticals's VRTX short percent of float has risen 27.71% since its last report. The company recently reported ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Short interest in Vertex Pharmaceuticals jumped 27.5% in May, hitting 4.82 million shares—just under 2% of the float. This ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

SpyGlass Pharma announced today that it closed a $75 million Series D financing round to support its drug delivery platform.